New drug duo aims to boost prostate cancer treatment success
NCT ID NCT06130995
Summary
This early-stage trial is testing the safety and effectiveness of combining two medications, relugolix and enzalutamide, for men with high-risk, locally advanced prostate cancer. Participants will take these drugs before and after their standard treatment, which is either radiation therapy or surgery to remove the prostate. The main goal is to see if this combination helps control the cancer better and improves the chance of a successful outcome.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.